CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Anastrozole +3 moredrug
Likely dose
Anastrozole 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03219476
NCT03219476Phase 2Completed
CompareCT.gov

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance

Medical College of Wisconsin·interventional·Posted Jul 17, 2017·Updated Apr 29, 2025

In Brief

A Phase 2 clinical trial evaluating Anastrozole, Letrozole, and 2 other interventions for Breast Cancer and Invasive Breast Cancer. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Invasive Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 17, 2017
Enrollment StartFeb 5, 2017
Primary CompletionFeb 4, 2020
Study CompletionMar 20, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.0 years ago

Interventions

Anastrozoledrug

1 mg once daily.

Letrozoledrug

2.5mg once daily.

Exemestanedrug

25 mg once daily.

Tamoxifendrug

20 mg once daily.